View clinical trials related to Metastatic ER+ Breast Cancer.
Filter by:Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.
Evaluate [18F]FES PET/CT uptake as a predictor of progression free survival in endocrine refractory recurrent or metastatic breast cancer patients starting a new therapy regimen including endocrine targeted therapy.